Celcuity LLC (CELC) is a Healthcare · Biotechnology company listed on NASDAQ. Price $81.02 (-4.58%), Market cap $6.82B, 52-week low–high $10.44 ~ $144.98.
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc.
Financial statements, price targets, institutional (13F) holdings and related news for Celcuity LLC are updated in real time on BlackAll Trade.
Celcuity LLC trades at $81.02 (-4.58%). Real-time quotes and charts are available on BlackAll Trade.
Celcuity LLC has a market cap of about $6.82B.
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidat